Deal Watch: Deal Volume On The Rise Heading Into J.P. Morgan
Executive Summary
Pfizer, Sanofi, Bristol Myers Squibb, Gilead’s Kite, Lilly’s Dermira, Janssen and Biogen among the major companies announcing transactions this week.
You may also be interested in...
Biogen Reassessing Gene Therapy From Nightstar Deal After Phase II/III Miss
BIIB112, the gene therapy candidate Biogen picked up in $877m acquisition of Nightstar, missed its primary endpoint in X-linked retinitis pigmentosa. Phase III data for BIIB111, also from Nightstar, are expected soon.
Finance Watch: DRI Healthcare’s Canadian IPO Enables More Royalty Deals
Public Company Edition: US initial public offerings are reawakening from a brief nap as Prometheus and Longboard prepare IPOs for launch. Also, Halozyme sells $700m worth of notes and Karuna’s $250m stock sale leads recent follow-on offerings.
Argenx Advances Efgartigimod Into China With Zai Lab Pact
Having just filed efgartigimod in the US, the European biotech has signed up Zai Lab to help develop and sell the potential autoimmune blockbuster in China, where an estimated 200,000 people live with myasthenia gravis.